These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 31838077)

  • 1. Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis.
    Hamzic S; Kummer D; Froehlich TK; Joerger M; Aebi S; Palles C; Thomlinson I; Meulendijks D; Schellens JHM; García-González X; López-Fernández LA; Amstutz U; Largiadèr CR
    Pharmacol Res; 2020 Feb; 152():104594. PubMed ID: 31838077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphisms in TYMS for Prediction of Capecitabine-Induced Hand-Foot Syndrome in Chinese Patients with Colorectal Cancer.
    Dong SQ; Wang TM; Zhang JB; He YQ; Xue WQ; Wu ZY; Yang DW; Cao LJ; Huang JW; Li XZ; Zhang PF; Zheng XH; Jia WH
    Cancer Res Treat; 2021 Jul; 53(3):724-732. PubMed ID: 33285053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.
    Rosmarin D; Palles C; Pagnamenta A; Kaur K; Pita G; Martin M; Domingo E; Jones A; Howarth K; Freeman-Mills L; Johnstone E; Wang H; Love S; Scudder C; Julier P; Fernández-Rozadilla C; Ruiz-Ponte C; Carracedo A; Castellvi-Bel S; Castells A; Gonzalez-Neira A; Taylor J; Kerr R; Kerr D; Tomlinson I
    Gut; 2015 Jan; 64(1):111-20. PubMed ID: 24647007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer.
    Lin S; Yue J; Guan X; Yuan P; Wang J; Luo Y; Fan Y; Cai R; Li Q; Chen S; Zhang P; Li Q; Ma F; Xu B
    Cancer Commun (Lond); 2019 Oct; 39(1):57. PubMed ID: 31601265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymidylate synthase gene variants as predictors of clinical response and toxicity to fluoropyrimidine-based chemotherapy for colorectal cancer.
    Castro-Rojas CA; Esparza-Mota AR; Hernandez-Cabrera F; Romero-Diaz VJ; Gonzalez-Guerrero JF; Maldonado-Garza H; Garcia-Gonzalez IS; Buenaventura-Cisneros S; Sanchez-Lopez JY; Ortiz-Lopez R; Camacho-Morales A; Barboza-Quintana O; Rojas-Martinez A
    Drug Metab Pers Ther; 2017 Dec; 32(4):209-218. PubMed ID: 29257755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.
    Meulendijks D; Henricks LM; Jacobs BAW; Aliev A; Deenen MJ; de Vries N; Rosing H; van Werkhoven E; de Boer A; Beijnen JH; Mandigers CMPW; Soesan M; Cats A; Schellens JHM
    Br J Cancer; 2017 May; 116(11):1415-1424. PubMed ID: 28427087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomics of fluorouracil -based chemotherapy toxicity.
    Matsusaka S; Lenz HJ
    Expert Opin Drug Metab Toxicol; 2015 May; 11(5):811-21. PubMed ID: 25800061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased risk of severe fluoropyrimidine-associated toxicity in patients carrying a G to C substitution in the first 28-bp tandem repeat of the thymidylate synthase 2R allele.
    Meulendijks D; Jacobs BA; Aliev A; Pluim D; van Werkhoven E; Deenen MJ; Beijnen JH; Cats A; Schellens JH
    Int J Cancer; 2016 Jan; 138(1):245-53. PubMed ID: 26189437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity.
    Loganayagam A; Arenas Hernandez M; Corrigan A; Fairbanks L; Lewis CM; Harper P; Maisey N; Ross P; Sanderson JD; Marinaki AM
    Br J Cancer; 2013 Jun; 108(12):2505-15. PubMed ID: 23736036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
    Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P
    Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gender-dependent association of
    Ioannou C; Ragia G; Balgkouranidou I; Xenidis N; Amarantidis K; Koukaki T; Biziota E; Kakolyris S; Manolopoulos VG
    Pharmacogenomics; 2021 Jul; 22(11):669-680. PubMed ID: 34100299
    [No Abstract]   [Full Text] [Related]  

  • 12. Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.
    Yap YS; Kwok LL; Syn N; Chay WY; Chia JWK; Tham CK; Wong NS; Lo SK; Dent RA; Tan S; Mok ZY; Koh KX; Toh HC; Koo WH; Loh M; Ng RCH; Choo SP; Soong RCT
    JAMA Oncol; 2017 Nov; 3(11):1538-1545. PubMed ID: 28715540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TYMS Gene Polymorphisms in Breast Cancer Patients Receiving 5-Fluorouracil-Based Chemotherapy.
    Chao YL; Anders CK
    Clin Breast Cancer; 2018 Jun; 18(3):e301-e304. PubMed ID: 28899623
    [No Abstract]   [Full Text] [Related]  

  • 14. Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer.
    García-González X; Cortejoso L; García MI; García-Alfonso P; Robles L; Grávalos C; González-Haba E; Marta P; Sanjurjo M; López-Fernández LA
    Oncotarget; 2015 Mar; 6(8):6422-30. PubMed ID: 25691056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.
    Joerger M; Huitema AD; Boot H; Cats A; Doodeman VD; Smits PH; Vainchtein L; Rosing H; Meijerman I; Zueger M; Meulendijks D; Cerny TD; Beijnen JH; Schellens JH
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):763-72. PubMed ID: 25677447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution of the most common polymorphisms in TYMS gene in Slavic population of central Europe.
    Pastorakova A; Chandogova D; Chandoga J; Luha J; Bohmer D; Malova J; Braxatorisova T; Juhosova M; Reznakova S; Petrovic R
    Neoplasma; 2017; 64(6):962-970. PubMed ID: 28895423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD.
    de With M; van Doorn L; Maasland DC; Mulder TAM; Oomen-de Hoop E; Mostert B; Homs MYV; El Bouazzaoui S; Mathijssen RHJ; van Schaik RHN; Bins S
    Biomed Pharmacother; 2023 Mar; 159():114232. PubMed ID: 36630849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology.
    Kelemen LE; Earp M; Fridley BL; Chenevix-Trench G; ; Fasching PA; Beckmann MW; Ekici AB; Hein A; Lambrechts D; Lambrechts S; Van Nieuwenhuysen E; Vergote I; Rossing MA; Doherty JA; Chang-Claude J; Behrens S; Moysich KB; Cannioto R; Lele S; Odunsi K; Goodman MT; Shvetsov YB; Thompson PJ; Wilkens LR; Dörk T; Antonenkova N; Bogdanova N; Hillemanns P; Runnebaum IB; du Bois A; Harter P; Heitz F; Schwaab I; Butzow R; Pelttari LM; Nevanlinna H; Modugno F; Edwards RP; Kelley JL; Ness RB; Karlan BY; Lester J; Orsulic S; Walsh C; Kjaer SK; Jensen A; Cunningham JM; Vierkant RA; Giles GG; Bruinsma F; Southey MC; Hildebrandt MAT; Liang D; Lu K; Wu X; Sellers TA; Levine DA; Schildkraut JM; Iversen ES; Terry KL; Cramer DW; Tworoger SS; Poole EM; Bandera EV; Olson SH; Orlow I; Vestrheim Thomsen LC; Bjorge L; Krakstad C; Tangen IL; Kiemeney LA; Aben KKH; Massuger LFAG; van Altena AM; Pejovic T; Bean Y; Kellar M; Cook LS; Le ND; Brooks-Wilson A; Gronwald J; Cybulski C; Jakubowska A; Lubiński J; Wentzensen N; Brinton LA; Lissowska J; Hogdall E; Engelholm SA; Hogdall C; Lundvall L; Nedergaard L; Pharoah PDP; Dicks E; Song H; Tyrer JP; McNeish I; Siddiqui N; Carty K; Glasspool R; Paul J; Campbell IG; Eccles D; Whittemore AS; McGuire V; Rothstein JH; Sieh W; Narod SA; Phelan CM; McLaughlin JR; Risch HA; Anton-Culver H; Ziogas A; Menon U; Gayther SA; Gentry-Maharaj A; Ramus SJ; Wu AH; Pearce CL; Lee AW; Pike MC; Kupryjanczyk J; Podgorska A; Plisiecka-Halasa J; Sawicki W; Goode EL; Berchuck A;
    Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30134598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thymidylate synthase pharmacogenetics.
    Marsh S
    Invest New Drugs; 2005 Dec; 23(6):533-7. PubMed ID: 16267625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
    Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; Werkhoven EV; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM
    Lancet Oncol; 2018 Nov; 19(11):1459-1467. PubMed ID: 30348537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.